
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes
By: Nutman A., Lellouche J., Temkin E., Daikos G., Skiada A., Durante-Mangoni E., Dishon-Benattar Y., Bitterman R., Yahav D., Daitch V., Bernardo M., Iossa D., Zusman O., Friberg L.E., Mouton J.W., Theuretzbacher U., Leibovici L., Paul M., Carmeli Y., Benattar Y.D., Dickstein Y., Zayyad H., Koppel F., Zak-Doron Y., Altunin S., Andria N., Neuberger A., Stern A., Petersiel N., Raines M., Karban A., Eliakim-Raz N., Elbaz M., Atamna H., Babich T., Adler A., Levi I., Daikos G.L., Pavleas I., Antoniadou A., Kotsaki A., Andini R., Cavezza G., Bertolino L., Giuffre G., Giurazza R., Cuccurullo S., Galdo M., Murino P., Cristinziano A., Corcione A., Zampino R., Pafundi P.C., Mouton J., Friberg L., Kristoffersson A., AIDA Study Group
Published in: Clinical Microbiology and Infection
SDGs : SDG 03 | Units: | Time: 2020 | Link
Description: Objectives: In vitro models showing synergism between polymyxins and carbapenems support combination treatment for carba (more…)